Page last updated: 2024-12-05
salicyl hydrazide
Description
Salicyl hydrazide is an organic compound with the formula C7H7N2O2. It is a white solid that is soluble in water and ethanol. Salicyl hydrazide is used in the synthesis of other organic compounds, such as dyes and pharmaceuticals. It is also used as an analytical reagent and a fungicide. Salicyl hydrazide is a potent inhibitor of monoamine oxidase (MAO), an enzyme that breaks down neurotransmitters such as dopamine, norepinephrine, and serotonin. Studies have shown that salicyl hydrazide has anti-inflammatory, analgesic, and antipyretic effects. It also exhibits antimicrobial activity against a range of bacteria and fungi. Salicyl hydrazide is being studied for its potential use in the treatment of Parkinson's disease, Alzheimer's disease, and other neurological disorders. It is also being investigated for its potential use in the treatment of cancer and other diseases. Its synthesis involves the reaction of salicylaldehyde with hydrazine hydrate.'
2-hydroxybenzohydrazide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 13637 |
| CHEMBL ID | 170058 |
| SCHEMBL ID | 161525 |
| MeSH ID | M0040770 |
Synonyms (60)
| Synonym |
|---|
| salicyclohydrazine |
| einecs 213-311-3 |
| salicoyl hydrazide |
| salicylic hydrazide |
| salicylohydrazide |
| nsc 652 |
| salicylic acid hydrazide |
| benzoic acid, 2-hydroxy-, hydrazide |
| o-hydroxybenzoylhydrazide |
| 2-hydroxybenzoylhydrazide |
| salicycic acid hydrazide |
| 936-02-7 |
| salicylic acid, hydrazide |
| salicyloylhydrazine |
| o-hydroxybenzhydrazide |
| nsc652 |
| 2-hydroxybenzoic acid hydrazide |
| o-hydroxylbenzhydrazide |
| salicyl hydrazide |
| o-hydroxybenzoylhydrazine |
| o-hydroxybenzoic acid hydrazide |
| salicyloyl hydrazide |
| nsc-652 |
| 2-hydroxybenzohydrazide |
| 2-hydroxybenzoylhydrazine |
| inchi=1/c7h8n2o2/c8-9-7(11)5-3-1-2-4-6(5)10/h1-4,10h,8h2,(h,9,11 |
| salicyloyl hydrazide, 98% |
| MAYBRIDGE1_007678 |
| STK053411 |
| BRD-K80800852-001-01-8 |
| HMS563E22 |
| CHEMBL170058 , |
| 2-hydroxy-benzoic acid hydrazide |
| S0242 |
| bdbm50056886 |
| AKOS000120449 |
| salicylhydrazide |
| BBL008416 |
| 2-hydroxybenzhydrazide |
| benzoylhydrazine, o-hydroxy |
| 2-hydroxybenzoic hydrazide |
| 2-hydroxybenzene-1-carbohydrazide |
| salicylyl hydrazine |
| FT-0612580 |
| SCHEMBL161525 |
| salicoylhydrazine |
| salicyclic acid hydrazide |
| DTXSID0061321 |
| salicyloylhydrazone |
| SEW 04563 |
| STR00212 |
| o-hydroxybenzoic hydrazide |
| 2-hydroxybenzoyl hydrazide |
| 2-hydroxybenzenecarboxylic acid hydrazide |
| mfcd00007599 |
| F1099-0053 |
| CS-W004074 |
| EN300-18163 |
| R5T5F3Q8HR |
| Z57241860 |
Protein Targets (1)
Inhibition Measurements
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID93518 | Inhibition of HIV-1 integrase enzyme by 3'-processing method (experiment 1) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
| Hydrazide-containing inhibitors of HIV-1 integrase. |
| AID93519 | Inhibition of HIV-1 integrase enzyme by 3'-processing method (experiment 2) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
| Hydrazide-containing inhibitors of HIV-1 integrase. |
| AID93522 | Inhibition of HIV-1 integrase enzyme by integration method (experiment 2) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
| Hydrazide-containing inhibitors of HIV-1 integrase. |
| AID93521 | Inhibition of HIV-1 integrase enzyme by integration method (experiment 1) | 1997 | Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
| Hydrazide-containing inhibitors of HIV-1 integrase. |
| AID1060953 | Cytotoxicity against human HCA-7 cells expressing COX-2, 5-LOX, CD44v6 assessed as growth inhibition after 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
| Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 26.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 26.67 (24.57) | | Research Supply Index | 2.83 (2.92) | | Research Growth Index | 5.18 (4.65) | | Search Engine Demand Index | 24.72 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |